Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Vaccinia virus A27L protein is a 110-amino-acid viral envelope protein conserved in the Orthopoxvirus genus, located on the surface of intracellular mature virions. It comprises a heparin-binding domain (residues 21-34), coiled-coil domain (residues 43-84) for oligomerization, and leucine zipper domain for A17 binding. The protein forms trimers as basic units that stack into hexamers via N-terminal and C-terminal interfaces, critical for self-assembly, disulfide-linked complex formation with A26, and biological functions including heparan sulfate binding for cell attachment, A26 packaging, mature virus egress, and modulation of plasma membrane fusion during entry. Mutations disrupting oligomerization impair plaque formation, virus egress, and A26 interaction, leading to increased fusion activity. As a neutralizing antibody target, its structure supports inhibitor development against poxvirus infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vaccinia virus A27L protein (A27L).